🔎 Trials Near Me

Akèy › Limfòm Burkitt › Oregon › Portland

Etid klinik pou Limfòm Burkitt nan Portland, OR

8 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Ap rekriteFaz 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
Laj 18 a 39 · Tout sèks · Mizajou Oct 2, 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Ap rekriteFaz 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Ap rekriteFaz 1/2
  • Oregon Health and Science University ( Site 1004), Portland
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ap rekriteFaz 2
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Ap rekriteFaz 2
  • Oregon Health & Science University, Portland
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Ap rekriteFaz 1/2
  • Oregon Health & Science University, Portland
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Study of SGR-1505 in Mature B-Cell Neoplasms

Ap rekriteFaz 1
  • Oregon Health and Science University - Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

Etid Limfòm Burkitt nan lòt vil

Lòt etid nan Portland

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.